|Project Title||Understanding and Discussing the Implications of the FDA’s Sentinel Initiative|
Tuesday, October 25, 2011
On October 25, the Engelberg Center hosted and expert workshop, “Understanding and Discussing the Implications of FDA’s Sentinel Initiative,” which focused on issues of importance for medical product developers.
This meeting brought together representatives to discuss the role of FDA’s pilot program, Mini-Sentinel, within FDA’s broader array of tools to monitor medical product safety and to discuss mechanisms for how developers could support and engage with FDA on Sentinel-related activities.
Mark McClellan MD, PhD; Engelberg Center for Health Care Reform, Brooking Institution, Washington DC
Janet Woodcock MD; U.S. Food and Drug Administration, Silver Spring, MD
Rachel Sherman MD, MPH, FACP; U.S. Food and Drug Administration, Silver Spring, MD
Melissa Robb RN; U.S. Food and Drug Administration, Silver Spring, MD
Richard Platt MD, MSc; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA